Suppr超能文献

那格列奈通过增强早期胰岛素分泌来改善糖耐量。

Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.

作者信息

Uto Yuko, Teno Shinichi, Iwamoto Yasuhiko, Omori Yasue, Takizawa Takao

机构信息

Saitamaken Saiseikai Kurihashi Hospital, Saitama, Japan.

出版信息

Metabolism. 2002 Jan;51(1):20-4. doi: 10.1053/meta.2002.29008.

Abstract

Nateglinide is a new, fast-onset, short-acting hypoglycemic agent, which increases early phase insulin secretion and the total amount of insulin secreted. However, it is not clear which of these effects contribute more to the decrease in postprandial plasma glucose (PG). To further clarify the pharmacologic actions of nateglinide, we investigated the changes in PG and insulin levels during meal tolerance tests with and without nateglinide. Subjects were 10 newly diagnosed and untreated inpatients with type 2 diabetes. After diet and exercise therapy for 1 week, nateglinide at 270 mg divided 3 times a day, was started. Meal tolerance tests were performed before (baseline) and after a single nateglinide administration (day 1), after 7 days of repeated administration (day 7), and after cessation of nateglinide on day 8. Mean fasting PG was 146 +/- 6 mg/dl (mean +/- SEM) at baseline and 130 +/- 6 mg/dL on day 7 (P =.0004). The 2-hour postprandial PG level was 226 +/- 10 mg/dL at baseline, 145 +/- 11 mg/dL on day 1 (P =.0008), and 190 +/- 15 mg/dL on day 8 (P =.08, baseline; P =.01, day 7). The mean fasting insulin level was 5.4 +/- 1.0 microU/mL at baseline and did not change significantly during the study. The 30-minute postprandial insulin level was 14.4 +/- 1.9 microU/mL at baseline, 39.5 +/- 4.5 microU/mL on day 1 (P =.0004), and 23.6 +/- 3.6 microU/mL on day 8 (P =.045, baseline; P =.010, day 7). The total insulin amount, in terms of area under the curve (AUC. IRI), was 3.99 +/- 0.7 x 10(3) microU/mL. min at baseline, 5.47 +/- 0.8 microU/mL. min on day 1 (P =.029), and 6.01 +/- 1.9 microU/mL. min on day 8 (P =.047 v baseline). The early phase of insulin secretion, based on the ratio of delta IRI to delta PG from fasting to 30 minutes after a meal was 0.15 +/- 0.13 at baseline, 1.44 +/- 0.26 on day 1 (P =.0009) and 0.26 +/- 0.06 on day 8 (P =.05 v day 1). After cessation of nateglinide, the postprandial PG level increased immediately. Although early phase insulin secretion returned nearly to the baseline level, total insulin secretion remained at a high level. These results suggested that early phase insulin secretion contributes more than total insulin secretion to the improvement of postprandial hyperglycemia in type 2 diabetes.

摘要

那格列奈是一种新型、起效快、作用时间短的降糖药物,它可增加早期胰岛素分泌及胰岛素分泌总量。然而,目前尚不清楚这些作用中哪一个对餐后血糖(PG)降低的贡献更大。为进一步阐明那格列奈的药理作用,我们研究了在有或无那格列奈的情况下进行餐耐量试验期间PG和胰岛素水平的变化。研究对象为10例新诊断且未接受治疗的2型糖尿病住院患者。经过1周的饮食和运动治疗后,开始给予那格列奈,剂量为270mg,每日3次。在单次给予那格列奈前(基线)、给药1天后(第1天)、重复给药7天后(第7天)以及第8天停用那格列奈后进行餐耐量试验。基线时平均空腹PG为146±6mg/dl(平均值±标准误),第7天时为130±6mg/dL(P = 0.0004)。餐后2小时PG水平在基线时为226±10mg/dL,第1天时为145±11mg/dL(P = 0.0008),第8天时为190±15mg/dL(与基线相比,P = 0.08;与第7天相比,P = 0.01)。平均空腹胰岛素水平在基线时为5.4±1.0μU/mL,在研究期间无显著变化。餐后30分钟胰岛素水平在基线时为14.4±1.9μU/mL,第1天时为39.5±4.5μU/mL(P = 0.0004),第8天时为23.6±3.6μU/mL(与基线相比,P = 0.045;与第7天相比,P = 0.010)。以曲线下面积(AUC.IRI)计算的总胰岛素量在基线时为3.99±0.7×10³μU/mL·min,第1天时为5.47±0.8μU/mL·min(P = 0.029),第8天时为6.01±1.9μU/mL·min(与基线相比,P = 0.047)。基于空腹至餐后30分钟的胰岛素增量(ΔIRI)与血糖增量(ΔPG)之比计算的早期胰岛素分泌在基线时为0.15±0.13,第1天时为1.44±0.26(P = 0.0009),第8天时为0.26±0.06(与第1天相比,P = 0.05)。停用那格列奈后,餐后PG水平立即升高。虽然早期胰岛素分泌几乎恢复到基线水平,但总胰岛素分泌仍维持在较高水平。这些结果表明,在2型糖尿病患者中,早期胰岛素分泌对餐后高血糖改善的贡献大于总胰岛素分泌。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验